NexImmune, Inc. (NEXI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol NEXI
- Company NexImmune, Inc.
- Price $0.23
- Changes Percentage 14.43
- Change 0.029
- Day Low $0.2
- Day High $0.23
- Year High $28.7
- Year Low $0.2
- Market Cap $320,774
- Price Avg 50 EMA (D) $0.52
- Price Avg 200 EMA (D) $3.82
- Exchange NASDAQ
- Volume 3,676
- Average Volume 5,838
- Open $0.2
- Previous Close $0.2
- EPS -18.51
- PE -0.01
- Earnings Announcement 2024-11-15 21:00:00
- Shares Outstanding $1,394,670
Company brief: NEXIMMUNE, INC. (NEXI )
- Healthcare
- Biotechnology
- Ms. Kristi Jones R.Ph.
- https://www.neximmune.com
- US
- N/A
- 02-12-2021
- US65344D2080
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.